| Schedule of significant expense categories |
| | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | June 30, | | June 30, | | June 30, | | June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Operating expenses: | | | | | | | | | | | | Clinical | $ | 2,301,995 | | $ | 1,630,084 | | $ | 4,111,415 | | $ | 3,447,316 | Chemical, manufacturing and controls | | 505,131 | | | 558,916 | | | 770,856 | | | 694,038 | Research and preclinical | | 731 | | | 8,094 | | | (4,903) | | | 32,228 | Regulatory | | 4,663 | | | 5,628 | | | 19,325 | | | 27,286 | Other research and development costs | | 433,999 | | | 367,221 | | | 1,019,605 | | | 806,073 | Total research and development | | 3,246,519 | | | 2,569,943 | | | 5,916,298 | | | 5,006,941 | General and administrative expenses | | 1,626,109 | | | 1,353,172 | | | 4,032,696 | | | 3,346,100 | IPR&D impairment | | 9,190,897 | | | — | | | 9,190,897 | | | — | Total operating expenses | $ | 14,063,525 | | $ | 3,923,115 | | $ | 19,139,891 | | $ | 8,353,041 | Sublease income | | (17,442) | | | — | | | (36,897) | | | — | Loss on debt conversion with related party | | — | | | — | | | — | | | 6,134,120 | Interest (income)/expense, net | | (66,349) | | | (111,379) | | | (143,699) | | | 35,711 | Exchange loss, net | | 30,569 | | | (4,532) | | | 36,429 | | | 18,742 | Net loss before income taxes | $ | 14,010,303 | | $ | 3,807,204 | | $ | 18,995,724 | | $ | 14,541,614 |
|